and led by researchers from John Hopkins Drugs discovered that two doses of psilocybin and supportive psychotherapy resulted in speedy, sizeable antidepressant effects.This Viewpoint examines how US states are reforming legislation to allow use of psychedelics for therapeutic use, but federal regulations consider these agents for being Schedule I d